Approval · Notice of Compliance 1688 · 2001
ABELCET: Notice of Compliance 1688
Issued April 6, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1688
- Date
- April 6, 2001
- Company
- The Liposome Company Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised indication: for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin b therapy
- Therapeutic class
- Antifungal agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABELCET | Not yet assigned | — |
Medicinal ingredients
- AMPHOTERICIN B 5 MG per ML